Hematologic Malignancies

Targeted Therapies Highlighted at This Year’s ASH Annual Meeting

In a webcast press briefing prior to the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition, journalists got a peek at some of the most anticipated abstracts. ASH President Kenneth C. Anderson, MD, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, Boston, shared the program committee’s picks for top news in the area of targeted therapies. 

Health-Care Policy

How ASCO’s New Initiatives Are Helping Oncologists Transition to MACRA

This year has been an important transitional period for oncology providers to start collecting their performance data to meet the requirements of the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program is a pay-for-performance system that emphasizes value-based, not quantity-incentivizing, care. MACRA replaces the sustainable growth rate formula as a mechanism for determining how the Centers for Medicare & Medicaid Services (CMS) reimburses physicians for their services and requires physicians to participate in one of two payment tracks: the Merit-Based Incentive Payment System (MIPS) or Advanced Alternative Payment Models (APMs).

Multiple Myeloma

Evidence-Based Support for Triplet Therapies in Multiple Myeloma

Over the past 15 years, multiple myeloma has garnered among the highest number of regulatory approvals by the U.S. Food and Drug Administration (FDA) for the management of all phases of the disease. This fast-expanding repertoire of treatment options has pushed the median survival of multiple myeloma patients from a few years to 10 years and longer in the current era1 and has cultivated an increasing belief that in most patients—with notable exceptions—the disease can be managed as a long-term, chronic condition. 


More Top Stories


James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects

Solid Tumors
Breast Cancer

Managing Neurotoxicity in Advanced Breast Cancer

Neurotoxicity in advanced breast cancer is not limited to chemotherapy-induced peripheral neuropathy, according to Matti Aapro, MD, of IMO Clinique de Genolier, Switzerland. Surgery, radiation therapy, and medical therapy can all have detrimental effects on either the central or peripheral...


ASH 2017: Sustained Benefit With Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma

The results of a pooled analysis of patients with relapsed or refractory mantle cell lymphoma (MCL) treated with ibrutinib (Imbruvica) were presented at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 151). The extended follow-up data demonstrated that...

Breast Cancer

Richard G. Gray, MSc, on Adjusting Adjuvant Chemotherapy Dosing: Results From an EBCTCG Analysis

International Society of Geriatric Oncology Awards Leaders at 2017 Conference

The International Society of Geriatric Oncology (SIOG) Annual Conference took place November 9–11, 2017, in Warsaw, Poland. Over 350 delegates representing 41 countries attended the meeting, along with more than 60 faculty from 22 countries. Stuart Lichtman, MD, SIOG President, and Attending...

Hematologic Malignancies

Recent Study Findings in CAR T-Cell Therapy for Neoplastic Malignancies

Here is an update on two recent clinical trials focusing on chimeric antigen receptor (CAR) T-cell therapy for neoplastic malignancies. Highlighted are the findings from an early-phase study in refractory aggressive lymphoma and a study in chronic lymphocytic leukemia after failure of ibrutinib...

ASH 2017: RESONATE-2 Trial: Patient-Reported Outcomes on Ibrutinib Treatment in Patients With CLL

At the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition, the 3-year follow-up data from the RESONATE-2 study (PCYC-1115/1116) were presented. The investigators found that patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...

Prostate Cancer

William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities

Barbara Savoldo, MD, PhD, Awarded Grant for Immunotherapy Research

University of North Carolina Lineberger Comprehensive Cancer Center researcher Barbara Savoldo, MD, PhD, has been awarded a $600,000, 3-year grant from to support research of an immunotherapy being developed. The grant will help fund clinical research into an investigational chimeric antigen...


Watch for More From ASH 2017

Phase III ASPIRE Trial of Carfilzomib in Relapsed Multiple Myeloma Overall survival results from the phase III ASPIRE trial will be detailed for the first time in an oral presentation by Stewart et al on Monday, December 11. The addition of carfilzomib to lenalidomide and...